Abstract
The effect of selective neurokinin receptor (NKR) antagonists for the NK1R (SR140,333), NK2R (SR48,968), and NK3R (SR142,801) on the visceromotor response to noxious colorectal distension (CRD) was examined. NKR antagonists or vehicle were given intrathecally (i.th.) to rats made hyperalgesic by intracolonic instillation of zymosan or after intracolonic instillation of saline (control). Given alone, the NK1R (up to 3 μg of SR140,333) and NK2R (up to 60 μg of SR48,968) antagonists tested failed to significantly affect responses to the noxious visceral stimulus. However, coadministration of 3 μg of SR140,333 and 60 μg of SR48,968 (both i.th.) significantly reduced responses to noxious CRD (p < 0.05 versus vehicle). The NK3R antagonist (60 μg of SR142,801) significantly reduced responses to noxious CRD when given alone to either hyperalgesic (zymosan-treated) or normal (saline-treated) rats (p < 0.05 versus vehicle for both groups). Responses of rats receiving the NK3R antagonist in combination with either the NK1R or the NK2R antagonist were not different from rats receiving the NK3R antagonist alone. These results suggest that activation of spinal NK1R and NK2R, presumably by their endogenous ligands (substance P and neurokinin A), maintain visceral hyperalgesia and support the notion that activation of NK3R (presumably by neurokinin B) is pronociceptive.
Footnotes
-
This study was supported by National Institutes of Health Grants NS19912 and DA02879 to G.F.G.. E.H.K. was supported by T32 GM07069.
- Abbreviations:
- SP
- substance P
- NKA
- neurokinin A
- NKB
- neurokinin B
- NK1R
- neurokinin 1 receptor(s)
- NK2R
- neurokinin 2 receptor(s)
- NK3R
- neurokinin 3 receptor(s)
- NKR
- neurokinin receptor(s)
- CRD
- colorectal distension
- EMG
- electromyographic
- i.th.
- intrathecal(ly)
- AUC
- area under the curve
- ANOVA
- analysis of variance
- DMSO
- dimethyl sulfoxide
- MPO
- myeloperoxidase
- IBS
- irritable bowel syndrome
- Received December 12, 2000.
- Accepted June 22, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|